Sushil Patel - Apr 10, 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Jack Anders, as Attorney-in-fact for Sushil Patel
Stock symbol
RVMD
Transactions as of
Apr 10, 2024
Transactions value $
-$43,531
Form type
4
Date filed
4/12/2024, 04:23 PM
Previous filing
Apr 3, 2024
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $36.2K +2.16K +13.73% $16.80 17.9K Apr 10, 2024 Direct F1, F2
transaction RVMD Common Stock Sale -$79.7K -2.16K -12.07% $37.00 15.7K Apr 10, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -2.16K -5.86% $0.00 34.6K Apr 10, 2024 Common Stock 2.16K $16.80 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023.
F2 Includes 10,450 restricted stock units.
F3 The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of June 16, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.